ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1214

Oxidative Stress from Use of Allopurinol – Is There a Reason for Patients with Gout to Take Vitamin C?

Lisa K. Stamp1, Peter T. Chapman2, John L. O'Donnell3, Irada Khalilova4, Rufus Turner4 and Anthony Kettle4, 1Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 2Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, 3Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, 4Pathology, University of Otago, Christchurch, Christchurch, New Zealand

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Allopurinol, gout and vitamins

  • Tweet
  • Email
  • Print
Session Information

Session Title: Metabolic and Crystal Arthropathies: Mechanisms of Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose During acute gout attacks neutrophils are activated and release a number of pro-inflammatory cytokines and enzymes. One of these enzymes is myeloperoxidase (MPO), which we have previously shown to be elevated in the circulation of patients with acute gout. Furthermore, MPO was associated with increased oxidation of urate as demonstrated by the increased concentration of allantoin in the plasma of these patients. Thus, oxidative stress is a feature of acute attacks of gout.     Allopurinol is the most commonly used urate lowering therapy. It is rapidly metabolised by aldehyde oxidase to oxypurinol as well as superoxide and hydrogen peroxide.  Oxypurinol exerts most of its inhibitory effects on xanthine oxidoreductase. In our previous work, allopurinol use was also associated with an increase in allantoin, indicating that it increases oxidative stress. The aim of this study was to determine the effects of allopurinol on plasma ascorbate (vitamin C), because its levels are sensitive to oxidative stress.

Methods Patients with gout and a serum urate >0.36mmol/L were recruited. Twenty patients already receiving allopurinol were randomised to either increase the dose of allopurinol or commence vitamin C 500mg/d. Twenty patients not receiving urate lowering therapy were randomised to either start allopurinol or vitamin C 500mg/d. Plasma ascorbate, allantoin, myeloperoxidase, oxypurinol and serum urate were measured at day 0 and week 8.

Results As expected at day 0, the 20 patients receiving allopurinol had significantly lower serum urate compared to those not on allopurinol (0.44 vs 0.54 mM p<0.001). Use of allopurinol was also associated with significantly lower plasma ascorbate levels (38.8 vs 56.7 µM p=0.03) and higher MPO levels (29.4 vs 18.0 µM p<0.001) at day 0.  There was a non-significant increase in serum allantoin.

In the 10 patients who commenced allopurinol there was a significant reduction between day 0 and week 8 in serum urate (0.57 vs 0.41 mM p=0.0003) and plasma ascorbate (54.2 vs 28.1 µM p=0.003) and an increase in plasma allantoin (2.6 vs 3.0 µM p=0.04). Plasma MPO was not affected by allopurinol. There was a significant negative correlation between plasma oxypurinol and plasma ascorbate concentrations (r=-0.54, p<0.0004).  For the 10 patients who stayed on their original dose of allopurinol, supplementation with vitamin C increased plasma vitamin C (48.4 vs 68.1 µM p=0.01) but had no effect on either urate or allantoin levels.  

Conclusion These results suggest that allopurinol promotes oxidative stress thereby depleting plasma ascorbate. Supplementation with vitamin C can increase plasma ascorbate in patients on allopurinol. The clinical significance of oxidative stress and low plasma ascorbate remains to be determined but our results indicate there may be a reason other than urate lowering for patients with gout to take vitamin C.


Disclosure:

L. K. Stamp,

Astra Zenec,

5,

Abbvie,

9,

PHARMAC,

6;

P. T. Chapman,
None;

J. L. O’Donnell,
None;

I. Khalilova,
None;

R. Turner,
None;

A. Kettle,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oxidative-stress-from-use-of-allopurinol-is-there-a-reason-for-patients-with-gout-to-take-vitamin-c/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences